Squamous cancer (SqCC) of the lung has a poor prognosis. With the advent of immunotherapy, prognosis has tended to improve; however, pseudoprogression poses a challenge to the management of immunotherapy. Herein, we discuss the case of a 47-year-old heavy smoker with advanced SqCC. The patient had recurrent disease after initial successful control of the tumor by concurrent radiochemotherapy, together with ample pleural effusion. Pleural effusion was well controlled with systematic nivolumab and intra-thoracic recombinant endostatin; however with simultaneous deterioration of performance and tumor progression. Nivolumab was maintained with the addition of nab-paclitaxel. The combination soon led to a partial response and rapid improvement of the patient's performance. During treatment of this case, we advocated the early control of pleural effusion as an indicator for pseudoprogression. Our experience might be helpful to identify pseudoprogression for the clinical management of immunotherapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119617 | PMC |
| http://dx.doi.org/10.1111/1759-7714.12799 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Outcomes in A Multi-center Cohort Involving 919 Patients with Hypertriglyceridemia-associated Acute Pancreatitis.
Am J Gastroenterol
January 2025
Center for Biomarker Discovery and Validation, National Infrastructures for Translational Medicine (PUMCH), Institute of Clinical Medicine, Peking Union Medical College Hospital, Beijing, China.
Objectives: Hypertriglyceridemia-associated acute pancreatitis (HTG-AP) is one of the most common etiologies of acute pancreatitis (AP) worldwide. Compared to other etiologies, patients with HTG-AP may develop more severe AP, but previous studies yielded controversial conclusion due to the lack of adequate adjustment for the confounders. Therefore, this study aimed to examine the possibility and risk factors of developing severe AP in HTG-AP.
View Article and Find Full Text PDFMultiple Kinase Small Molecule Inhibitor Tinengotinib (TT-00420) Alone or With Chemotherapy Inhibit the Growth of SCLC.
Cancer Sci
January 2025
Department of Medical Oncology, Jilin Cancer Hospital, Changchun, China.
There is an urgent need to develop new targeted treatment agents for small cell lung cancer (SCLC). Tinengotinib (TT-00420) is a novel, multi-targeted, and spectrally selective small-molecule kinase inhibitor that has shown significant inhibitory effects on certain solid tumors in preclinical studies. However, its role and mechanism of action in SCLC remain unclear.
View Article and Find Full Text PDFFirst case report of isolated pleural cysticercosis demonstrating pleuroscopic findings.
Respir Med Case Rep
December 2024
Pulmonary and Critical Care Division, Department of Medicine, Phramongkutklao Hospital, Bangkok, Thailand.
Pulmonary cysticercosis is a rare manifestation of human cysticercosis, which mostly occurs in developing countries. The disease can affect the lung parenchyma and pleura, resulting in pulmonary nodules, pneumonitis, lung cavities, or pleural effusion. We herein present a case involving a man of advanced age who presented with symptomatic eosinophilic pleural effusion.
View Article and Find Full Text PDFBackground: Light-chain cardiac amyloidosis (AL-CA) is associated with structural and functional changes in the left atrium and left ventricle. This study aims to assess the value of the left atrioventricular coupling index (LACI) assessed by three-dimensional echocardiography (3DE) for predicting primary outcome in AL-CA.
Methods: Participants with biopsy-confirmed AL-CA from April 2022 to February 2024 were prospectively analysed.
Accuracy of Fully Automated and Human-assisted AI-based CT Quantification of Pleural Effusion Changes after Thoracentesis.
Radiol Artif Intell
January 2025
From the Department of Radiology (E.J.H., S.K., H.K., D. K., S.H.Y.) and Medical Research Collaborating Center (H.H.), Seoul National University Hospital, 101 Daehak- ro, Jongno-gu, Seoul 03080, Korea; Department of Radiology, Seoul National University College of Medicine (E.J.H., H.K., S.H.Y.), Seoul, Korea; Department of Radiology, Hanyang University Medical Center, Hanyang University College of Medicine (S-J.Y., Seoul, Korea).
Quantifying pleural effusion change on chest CT is important for evaluating disease severity and treatment response. The purpose of this study was to assess the accuracy of artificial intelligence (AI)-based volume quantification of pleural effusion change on CT images, using the volume of drained fluid as the reference standard. Seventy-nine participants (mean age, 65 ± [SD] 13 years; 47 male) undergoing thoracentesis were prospectively enrolled from October 2021 to September 2023.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!